Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation.

From Beckman Coulter Life Sciences - Flow Cytometry 5 May 2015

Ebola survivors face long-term adverse health effects: Study

Ebola survivors experienced negative health effects that persisted more than two years after the 2007-2008 Bundibugyo ebolavirus (BDBV) outbreak in Uganda that claimed 39 lives. These findings are detailed in a paper published online today in Lancet ID.

23 Apr 2015

GenVec, Laboratory of Malaria Immunology and Vaccinology sign research collaboration agreement

GenVec, Inc. today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

21 Apr 2015

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus.

27 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology.

23 Mar 2015

Study reveals causes of community-acquired pneumonia in children

With the chill of winter comes a spike in community-acquired pneumonia (CAP), which spreads more easily as people retreat indoors and come into close contact. The lung infection triggers persistent coughing, chest pain, fever, and difficulty breathing, and is particularly hard on the very young and the very old. In fact, pneumonia is the leading cause of hospitalization among U.S. children, with estimated medical costs of $1 billion annually.

26 Feb 2015

Study points respiratory viruses as the most common cause of childhood pneumonia

Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine.

26 Feb 2015

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine.

23 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.

18 Dec 2014

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Peroxisome proliferator–activated receptor α exerts protective effects on retinal pericytes, shows research that explains why fenofibrate is protective against diabetic retinopathy.

1 Dec 2014

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.

27 Nov 2014

Research shows that copper could help to prevent Ebola spread

Research from the University of Southampton has indicated that copper could help to prevent the spread of Ebola.

30 Oct 2014

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine.

10 Oct 2014

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae.

From Luminex 30 Sep 2014

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences.

9 Sep 2014

Experimental vaccine protects monkeys exposed to Ebola virus

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector (called chimp adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health (NIH) scientists and their collaborators.